Steve Gardner | Co-founder & CEO
Steve is a serial technology entrepreneur with over 25 years’ experience developing and commercializing ground-breaking data science and informatics in the healthcare, life sciences and agri-food sectors.
Never afraid to innovate, Steve has an established track record in building world-class companies, teams and products working at senior levels in the UK, EU and US for Fortune 500 and start-up companies. He is a former Global Director of Research Informatics for Astra A/B and has consulted with drug discovery and safety teams in over 20 biopharma companies. Steve has held CxO positions and led teams in several international businesses, supplying innovative computational biology, chemistry and semantic data integration tools. He was involved in Oxford Molecular's IPO and the acquisition and integration of 11 companies. He is also an Advisory Council member for Breast Cancer Now and UKCRC.
Simon Beaulah | SVP of Healthcare & Head of US Operations
Simon joined PrecisionLife in September 2020 and leads our healthcare partnering program having spent more than 20 years managing product and business strategy teams for innovative informatics businesses in the healthcare and life science ecosystems.
Before joining the company, Simon was Director of Healthcare at Linguamatics, leading their healthcare business unit for seven years, driving their go-to-market and partnering strategy, product focus, and supporting the integration into IQVIA. The healthcare unit achieved significant commercial success during that time, showing consistent and substantial annual average growth. Prior to that, he spent five years at InforSense and IDBS leading product marketing efforts and served as Marketing Director of Translational Medicine at IDBS Healthcare.
Véronique Bouchet | Chief Medical Officer
Véronique is a medical expert and strategic thinker with over 30 years’ experience in the pharmaceutical, biotech and digital health sectors.
She is a former Director of Corporate Strategy and Head of Venture Strategy at AstraZeneca, where she was responsible for global corporate venturing activities, including the creation and $40M financing of the company’s first spinout, Albireo Pharma. She has also held posts in clinical research, licensing, M&A, venture capital and the NHS.
This varied experience has given her an in-depth understanding of what is required to translate cutting edge science into commercial reality. Véronique is the Senior Independent Director of International Biotechnology Trust plc. and of the Stevenage Bioscience Catalyst. She is a member of Oxford University's Expert Panel supporting The Royal Society Entrepreneur in Residence (EiR) scheme, and also sits on the Advisory Board of QMUL School of Business and Management. She was recognised as one of 50 Movers and Shakers challenging the status quo to bring better health in BioBusiness 2019.
Gert Møller | Co-founder & Chief Analytics Officer
Gert is an entrepreneur with over 20 years of experience of driving new innovations in AI, precision medicine and digital health.
He invented and developed some of the novel AI solutions which are the foundation of precisionlife’s core technology. He is the principal inventor on our patents for the RACE technologies and has won a number of major awards for his innovations. He began applying RACE in 1996 across a range of industry specific and safety critical applications including nuclear power plant design, consumer electronics and railroad safety systems. Working with our multi-disciplinary team of scientists, engineers and commercial experts, Gert has also helped solve challenges in clinical genomics and bioinformatics including conducting population scale genomics studies based on multiple combinations of SNPs or other markers. His inventions enable the solution of problems on large & complex systems several orders of magnitude faster than other existing statistical or machine learning methods.
Maria Parrag | Financial Director
Maria is a commercially astute, hands-on finance professional with strong business analysis and modelling skills.
She is responsible for organizing the financial management of the Group, which includes all financial operations, cash management, compliance, tax and statutory reporting. Maria is a chartered management accountant who has held a number of finance leadership positions across large listed companies as well as SMEs and start-ups. She manages the collection and collation of information from across the Group’s operations and offices and reporting to investors and the Board. Maria has experience working within multiple sectors including the publishing, software technology, music media and manufacturing industries.
Mark Strivens | Chief Technology Officer
Mark is the planner and organiser who coordinates the design and delivery of precisionlife’s innovative platforms and projects.
He has a long and varied career in bioinformatics in both human and animal disease studies across academia, industry and the clinical sectors. Mark started his career building the informatics group for the MRC’s Mammalian Genetics Unit before moving into the bio-pharmaceutical industry to apply his knowledge to the development of novel therapeutic programs. He then joined Baylor College of Medicine to provide the medical genetics community with some of the early clinical genetic testing services and to participate in rare disease research projects. Mark’s career has encompassed the design and development of complex scientific software, clinical lab IT systems, database and informatics products and this background is perfectly suited to the challenge of bringing together all of the streams of scientific, technical and clinical innovation in our platforms.
We are proud to be certified carbon neutral, achieved by proactively reducing our carbon footprint and offsetting our remaining carbon emissions. We chose the Climate Care BURN Stoves project, which won the 2015 Ashden International Clean Energy for Women and Girls Award.
Equality and Diversity
We are an equal opportunities employer. We are committed to ensuring that no employee or prospective employee receives less favourable treatment on the grounds of gender, sexual orientation, marital status, disability, race, colour or national origin.